CA2232815A1 - Methode d'inhibition de la destruction par le systeme immunitaire de cellules vivantes greffees - Google Patents

Methode d'inhibition de la destruction par le systeme immunitaire de cellules vivantes greffees Download PDF

Info

Publication number
CA2232815A1
CA2232815A1 CA002232815A CA2232815A CA2232815A1 CA 2232815 A1 CA2232815 A1 CA 2232815A1 CA 002232815 A CA002232815 A CA 002232815A CA 2232815 A CA2232815 A CA 2232815A CA 2232815 A1 CA2232815 A1 CA 2232815A1
Authority
CA
Canada
Prior art keywords
cells
subject
viable
insulin
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002232815A
Other languages
English (en)
Inventor
Collin J. Weber
Mary K. Hagler
Peter S. Linsley
Judith A. Kapp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2232815A1 publication Critical patent/CA2232815A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé permettant d'inhiber la destruction de cellules vivantes greffées chez un sujet par le système immunitaire dudit sujet. Ce procédé consiste à a) enfermer, avant la greffe, les cellules vivantes, ou du tissu contenant les cellules vivantes, dans un dispositif comportant une membrane semi-perméable, et b) à traiter le sujet avec une substance qui inhibe un phénomène de costimulation du système immunitaire, administrée en quantité utile pour empêcher le système immunitaire du sujet de répondre auxdites cellules ou audit tissu ainsi enfermés. Selon un mode de réalisation, la substance inhibant un phénomène de costimulation du système immunitaire est CTLA4. Cette invention concerne également un mode de traitement du diabète chez un sujet consistant à a) enfermer des cellules vivantes productrices d'insuline, ou du tissu contenant de telles cellules, dans un dispositif comportant une membrane semi-perméable; b) à greffer chez le sujet une quantité efficace de cellules vivantes productrices d'insuline ainsi enfermées; et c) à traiter le sujet avec une quantité utile d'une substance qui inhibe un phénomène de costimulation du système immunitaire.
CA002232815A 1995-09-27 1996-09-27 Methode d'inhibition de la destruction par le systeme immunitaire de cellules vivantes greffees Abandoned CA2232815A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US437595P 1995-09-27 1995-09-27
US60/004,375 1995-09-27

Publications (1)

Publication Number Publication Date
CA2232815A1 true CA2232815A1 (fr) 1997-04-03

Family

ID=21710493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232815A Abandoned CA2232815A1 (fr) 1995-09-27 1996-09-27 Methode d'inhibition de la destruction par le systeme immunitaire de cellules vivantes greffees

Country Status (4)

Country Link
JP (1) JP2000500121A (fr)
AU (1) AU721737B2 (fr)
CA (1) CA2232815A1 (fr)
WO (1) WO1997011607A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041634B2 (en) * 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes

Also Published As

Publication number Publication date
AU721737B2 (en) 2000-07-13
WO1997011607A1 (fr) 1997-04-03
JP2000500121A (ja) 2000-01-11
AU7378296A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
US7041634B2 (en) Method of inhibiting immune system destruction of transplanted viable cells
Narang et al. Biological and biomaterial approaches for improved islet transplantation
US5227298A (en) Method for microencapuslation of cells or tissue
DE60225914T2 (de) Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
Marigliano et al. Pig-to-nonhuman primates pancreatic islet xenotransplantation: an overview
Gray et al. Islet cell transplantation for insulin-dependent diabetes mellitus: perspectives from the present and prospects for the future
Weber et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice
Kenyon et al. Islet transplantation: present and future perspectives
Weber et al. Evaluation of graft‐host response for various tissue sources and animal models
WO1996031223A1 (fr) Procede de pretraitement de cellules ou tissus viables destines a etre contenus dans une enveloppe semi-permeable
Zeng et al. Long-term survival of donor-specific pancreatic islet xenografts in fully xenogeneic chimeras (WF rat→ B10 mouse)
Safley et al. Proliferative and cytokine responses in CTLA4-Ig-treated diabetic NOD mice transplanted with microencapsulated neonatal porcine ICCs
AU721737B2 (en) Method of inhibiting immune system destruction of transplanted viable cells
WO1997011607A9 (fr) Methode d'inhibition de la destruction par le systeme immunitaire de cellules vivantes greffees
EP0877555B1 (fr) Utilisation d'un inhibiteur d'un processus de costimulation du système immunitaire pour la préparation d'un médicament pour la prévention de la destruction par le systeme immunitaire de cellules vivantes non embryonnaires greffées
Weber et al. Long-term survival of poly-l-lysine-alginate microencapsulated islet xenografts in spontaneously diabetic NOD mice
Juang Islet transplantation: an update
Arefanian et al. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice
AU710637B2 (en) Method for synthesizing microcapsules of predetermined permeability
Warnock et al. Human pancreatic islet transplantation
Sandberg et al. Immunosuppression, Macroencapsulation and Ultraviolet‐B Irradiation as Immunoprotection in Porcine Pancreatic Islet Xenotransplantation
Emerich Islet transplantation for diabetes: current status and future prospects
Kim et al. Xenogeneic pancreatic islet cell transplantation—Application of pig cells and techniques for clinical islet cell xenotransplantation
Hawthorne Beta cell therapies for type 1 diabetes
Kenyon et al. Experimental approaches to the prevention of islet rejection

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead